Soon to be Phase 1 Trial: AK157D1 a New B7‑H3–Targeted ADC in Advanced Prostate Cancer

The investigational B7‑H3–targeting antibody–drug conjugate AK157D1, recently cleared for a Phase I trial in advanced solid tumors, is especially compelling from a prostate cancer perspective because B7‑H3 (CD276) is one of the most uniformly expressed and biologically aggressive surface targets across the full disease continuum, from hormone‑sensitive to castration‑resistant and neuroendocrine phenotypes. Unlike PSMA, which can be downregulated as tumors become AR‑negative or acquire neuroendocrine features, B7‑H3 is negatively regulated by androgen receptor signaling, meaning its expression tends to stay high or even increase when prostate cancer progresses to more lethal, treatment‑refractory states, making it an attractive “anchor” target for ADC‑based strategies in metastatic CRPC and beyond.

Large translational datasets, including the JHU‑PANORAMA single‑cell atlas and metastatic rapid‑autopsy cohorts, show that B7‑H3 is broadly and stably expressed on prostate cancer cells across primary and metastatic sites, with high expression associated with adverse outcomes in primary and hormone‑sensitive disease and maintained expression in CRPC and neuroendocrine prostate cancer. This pattern aligns with earlier immunohistochemistry studies demonstrating that B7‑H3 is present in the vast majority of prostate cancers and that strong staining intensity correlates with extracapsular extension, seminal vesicle invasion, metastatic recurrence, and cancer‑specific death, reinforcing its link to aggressive biology and poor prognosis. Importantly, B7‑H3 expression is enriched in tumors harboring DDR defects (such as BRCA2 and ATM alterations) and PTEN/TP53 loss, genomic contexts that define some of the highest‑risk prostate cancers and are often under‑served by current targeted therapies.

AK157D1 is designed to exploit this biology by delivering a potent topoisomerase I inhibitor payload (DXd) directly to B7‑H3–expressing prostate cancer cells via a humanized IgG1κ antibody linked through a cleavable MC‑AAA linker, a configuration intended to maximize tumor killing while limiting exposure to normal tissues where B7‑H3 expression is low. Preclinical data summarized in company disclosures suggest that AK157D1 has strong antitumor activity and a favorable safety profile, with claims of reduced hematologic toxicity and lower risk of interstitial lung disease compared with earlier ADCs, although detailed quantitative data in prostate cancer models have not yet been published. Even without prostate‑specific efficacy data at this stage, the broader B7‑H3 ADC experience in prostate cancer is encouraging: other B7‑H3–directed ADCs, including duocarmycin‑based constructs, have shown activity in preclinical mCRPC models, and combinations of B7‑H3 ADCs with BCL‑XL inhibitors have demonstrated enhanced tumor growth inhibition in p53‑proficient and ‑deficient mCRPC, highlighting the potential for rational combinations that could be explored with AK157D1 in the future.

From a therapeutic strategy standpoint, AK157D1 fits naturally into emerging “continuum‑wide” approaches that aim to maintain target coverage as prostate cancer evolves under treatment pressure. Recent analyses position B7‑H3 as a central node for combinatorial therapy because it achieves high combinatorial scores with other clinically relevant targets such as TROP‑2, NECTIN4, and KLK2, supporting concepts like bispecific antibodies or dual‑ADC regimens anchored on B7‑H3 to limit escape and sustain pressure across disease states, including AR‑negative and neuroendocrine variants that are typically excluded from PSMA‑targeted radioligand therapies. Plans to develop AK157D1 in combination with PD‑1/VEGF and PD‑1/CTLA‑4 bispecific antibodies align with this logic, offering a potential way to pair direct cytotoxic payload delivery with immune checkpoint blockade and anti‑angiogenic effects, which could be especially relevant in prostate cancer where single‑agent immunotherapy has so far shown limited benefit.

For prostate cancer patients and clinicians, the key implication is that B7‑H3–targeted ADCs like AK157D1 could become an important option for advanced disease, particularly in settings where PSMA expression is low or heterogeneous, where tumors have DDR defects or PTEN/TP53 loss, or where neuroendocrine or “double‑negative” phenotypes limit the utility of current targeted approaches.

Source.